Lucid Diagnostics Files Prospectus To Raise Up To $175M Through Sale Of Stock, Debt And Warrants

Lucid Diagnostics Inc.

 

$175,000,000

 

Common Stock, Preferred Stock, Debt Securities, Warrants and Units

 

We may offer and sell from time to time shares of common stock, shares of preferred stock, debt securities, warrants and/or units comprised of one or more of the other classes of securities offered hereby, at an aggregate initial offering price not to exceed $175,000,000. The securities may be offered separately, together, or in series, and in amounts, at prices and on other terms to be determined at the time of each offering. We will specify the terms of the securities being offered in one or more prospectus supplements, which may also supplement, update or amend information contained or incorporated by reference in this prospectus.

 

We may sell the securities directly to investors, to or through underwriters or dealers or through agents designated from time to time, among other methods. The prospectus supplement for each offering will describe in detail the specific plan of distribution for the securities. The prospectus supplement also will set forth the price to the public of such securities, any placement agent's fees or underwriter's discounts and commissions, and the net proceeds we expect to receive from the sale of the securities.

 

Our common stock is listed for trading on the Capital Market of The Nasdaq Stock Market LLC, or "Nasdaq," under the symbol "LUCD." On December 4, 2025, the last reported sale price of our common stock was $1.06. As of the date of this prospectus, none of the other securities that we may offer by this prospectus are listed on any national securities exchange or automated quotation system.